How Thermo Fisher Scientific Makes its Money: Revenue Breakdown

How Does Thermo Fisher Scientific Make its Money?

Thermo Fisher Scientific is the world’s largest life sciences tools and services company by revenue, headquartered in Waltham, Massachusetts. It serves research laboratories, hospitals, pharmaceutical and biotechnology companies, governments, and industrial manufacturers across 180+ countries. The company’s product catalogue spans scientific instruments, analytical equipment, reagents and consumables, cell culture media, drug manufacturing services, and laboratory software — effectively serving as a full-spectrum supplier to anyone doing science at scale.

Thermo Fisher built its current scale through decades of acquisitions: the 2006 merger of Thermo Electron and Fisher Scientific created the company; subsequent purchases of Life Technologies (2014, $13.6B), Patheon (2017, $7.2B), PPD (2021, $21B), and dozens of smaller bolt-ons have made it the dominant player in life sciences supply. The company’s strategic pitch to customers is integration — buy instruments, reagents, software, and manufacturing services all from one supplier under long-term contracts.

In fiscal year 2025 (ended December 31, 2025), Thermo Fisher generated $44.56B in total revenue, up 3.9% from $42.88B in FY2024. Organic revenue growth was approximately 2.0%. The post-COVID destocking cycle that suppressed revenue in FY2023–2024 has largely worked through the system, and the business is returning to its historical mid-single-digit organic growth trajectory.

Thermo Fisher Scientific (TMO) Business Model

Thermo Fisher earns money through three types of revenue:

1. Consumables (~42% of revenue, $18.66B in FY2025): Single-use products that are purchased repeatedly. This includes reagents for research, cell culture media, PCR kits, sample preparation products, protective laboratory clothing, and hundreds of thousands of other items that get used once and repurchased. Consumables carry higher gross margins than instruments and provide steady, recurring revenue regardless of capital equipment cycles.

2. Services (~42% of revenue, $18.59B in FY2025): Two major service streams. First, biopharma contract development and manufacturing services (CDMO) — Thermo Fisher manufactures active pharmaceutical ingredients and drug products for biopharmaceutical companies through its Patheon and PPD businesses. Second, clinical research organisation (CRO) services — managing clinical trials for drug developers through PPD. Together these make Thermo Fisher one of the largest CDMO/CRO companies in the world, deeply embedded in pharmaceutical pipelines.

3. Instruments (~16% of revenue, $7.30B in FY2025): Scientific instruments including mass spectrometers, electron microscopes, chromatography systems, flow cytometers, and laboratory automation platforms. Instruments are sold once (capital expenditure for customers), carry lower margins than consumables, but generate long-term recurring revenue through service contracts, software subscriptions, and the consumables required to operate them.

The business model has a powerful flywheel: instruments create installed base that drives consumable and service revenue for years. A mass spectrometer sold to a pharmaceutical laboratory in year one generates ongoing reagent, calibration, and maintenance revenue for 10–15 years.

Thermo Fisher Scientific Competitors

Thermo Fisher Scientific’s key competitors and comparable public companies in the life sciences sector include Danaher, Abbott Laboratories, and Eli Lilly. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Thermo Fisher Scientific stacks up by comparing their revenue breakdown, margins, and growth metrics.

Revenue Breakdown

FY2025 ended December 31, 2025. Financial data sourced from Thermo Fisher Scientific SEC Filings.

Laboratory Products & Biopharma Services — 54% of Revenue

The largest segment at $23.98B in FY2025 (+3.5%), this division encompasses two distinct business lines grouped together:

Laboratory Products: Distribution and private-label sale of laboratory consumables, chemicals, safety equipment, and supplies. Thermo Fisher operates one of the world’s largest laboratory supply distribution businesses, sourcing products from thousands of manufacturers and distributing them through its Fisher Scientific brand. This is a high-volume, lower-margin channel that benefits enormously from scale economies.

Biopharma Services (Patheon/PPD): Contract development and manufacturing services (CDMO) for pharmaceutical and biotech companies, and contract research services (CRO) through PPD Clinical Research. Biopharma customers outsource drug manufacturing and clinical trial management to Thermo Fisher to reduce capital investment and access specialist expertise. This is one of the fastest-growing and most strategically important parts of the business, as pharmaceutical R&D spending and outsourcing penetration both trend higher over time.

Segment operating income was $3.35B in FY2025, an operating margin of approximately 14% — lower than the company average because the distribution channel within this segment is lower-margin than instruments or reagent manufacturing.

Life Sciences Solutions — 23% of Revenue

Life Sciences Solutions ($10.37B, +7.7%) is the highest-margin segment and the heart of Thermo Fisher’s scientific differentiation. It covers:

• Biosciences: Research reagents, antibodies, proteins, cell culture media, transfection reagents, and molecular biology tools sold to academic research institutions, pharmaceutical companies, and biotech companies
• Genetic Sciences: Next-generation sequencing systems and reagents, PCR instruments and kits (Thermo Fisher is the global leader in PCR through its Applied Biosystems brand), and genetic analysis platforms
• Protein and Cell Biology: Mass spectrometry for proteomics, flow cytometry systems, and cell analysis platforms

This segment benefited from an 7.7% revenue bounce in FY2025 as the post-COVID inventory destocking cycle in biotech and pharma concluded and customers resumed normal ordering patterns. Segment operating income was $3.77B at a ~36% operating margin — roughly double the company average — reflecting the premium pricing of proprietary reagents and instruments where Thermo Fisher has limited competition.

Analytical Instruments — 17% of Revenue

Analytical Instruments ($7.55B, flat at +1.2%) includes Thermo Fisher’s portfolio of high-precision laboratory instruments:

• Chromatography & Mass Spectrometry: Used in pharmaceutical quality control, environmental testing, food safety, and research. Thermo Fisher’s Orbitrap mass spectrometers are the industry standard for high-resolution protein analysis.
• Electron Microscopy: Thermo Fisher (through the FEI acquisition) is the world leader in transmission electron microscopes (TEM) and scanning electron microscopes (SEM) used for materials science, semiconductor inspection, and structural biology.
• Chemical Analysis: Portable and benchtop analysers for industrial and field applications.

Instrument revenue was essentially flat in FY2025 as large capital equipment purchasing by pharmaceutical and semiconductor customers remained cautious. Segment operating income was $1.74B at approximately 23% margin.

Specialty Diagnostics — 10% of Revenue

Specialty Diagnostics ($4.68B, +3.6%) covers diagnostic products for clinical and industrial settings: transplant diagnostics (immunosuppressant drug monitoring), clinical chemistry reagents, microbiology products, and allergy/autoimmunity testing. This segment serves hospital laboratories and clinical reference labs and benefits from recurring consumable demand driven by patient testing volumes rather than research budgets.

Segment operating income was $1.26B at approximately 27% margin — above the company average, reflecting the premium pricing possible in regulated diagnostic markets where switching costs are high.

Thermo Fisher Scientific (TMO) Income Statement

All values in millions USD.

Thermo Fisher Scientific (TMO) Key Financial Metrics

• Gross Margin: 40.9% — Consistent and stable. Thermo Fisher’s blended margin reflects the mix of high-margin reagent/instrument revenue (~50%+ margins) averaging down with lower-margin distribution and services revenue (~20–25% margins). The gross margin has been in the 40–42% range consistently.
• Operating Margin: 17.4% — Solid for a diversified industrial/life sciences company. Thermo Fisher targets ~20%+ adjusted operating margin, with GAAP margin lower due to acquisition-related amortisation charges.
• Revenue Growth: +3.9% — A recovery from near-flat growth in FY2024 (+0.05%) and a decline in FY2023 (-4.6%). FY2023’s decline was driven by the unwinding of COVID-related revenue (vaccines, testing) and post-COVID biotech destocking. FY2025’s return to growth reflects normalisation of end-market demand.
• Free Cash Flow: $6.29B (14.1% margin) — Thermo Fisher consistently converts ~90%+ of net income to free cash flow, reflecting the capital-efficient nature of its instrument and consumable businesses. FCF declined from $7.27B in FY2024 due to higher capital expenditures.

Is Thermo Fisher Scientific Profitable?

Yes, Thermo Fisher is highly profitable. The company reported net income of $6.70B on $44.56B in revenue in FY2025, a net margin of 15.2%. Operating income was $7.75B at a 17.4% operating margin. The company has been consistently profitable for over two decades, with net income growing every year except FY2023 (when COVID revenue unwound).

Thermo Fisher uses its free cash flow primarily for acquisitions and share buybacks. The company has reduced its share count from 394M (FY2021) to 376M (FY2025) through buybacks. It also pays a small but growing dividend ($1.72 per share in FY2025, up from $1.56 in FY2024).

Where Does Thermo Fisher Spend its Money?

• Cost of Revenue ($26.3B / 59% of revenue): Manufacturing costs for instruments and reagents, plus the cost of products procured for distribution. The largest cost line by far; reducing it requires either product mix shift toward higher-margin reagents and services, or manufacturing efficiency gains.
• Selling, General & Administrative ($8.7B / 19.6% of revenue): Global salesforce (Thermo Fisher employs ~125,000 people), field service engineers maintaining customer instruments, marketing, and corporate overhead. This is the biggest controllable expense line.
• Research & Development ($1.4B / 3.1% of revenue): Relatively modest R&D for a company this size. Thermo Fisher’s competitive advantage comes more from scale, supply chain, and customer relationships than from frontier scientific innovation. Most product development occurs within acquired businesses that bring proprietary platforms.
• Acquisition spending: Not reflected in the income statement but historically $2–5B annually on bolt-on acquisitions. This is the primary growth mechanism and the core of Thermo Fisher’s compounding strategy.

Thermo Fisher Scientific (TMO): What to Watch

1. Organic revenue growth recovery — Organic growth of ~2% in FY2025 is below Thermo Fisher’s long-term target of mid-to-high single digits. The pace of biotech funding recovery, pharmaceutical R&D spending, and academic research budgets will determine whether 2025 is a transition year or a structural deceleration.
2. NIH and government research funding — Proposed cuts to U.S. NIH funding under the current administration represent a genuine near-term risk. Academic research laboratories and NIH-funded biotech companies are significant Thermo Fisher customers. Any multi-year reduction in federal research spending would suppress consumable and instrument demand.
3. Biopharma CDMO/CRO pipeline — The Patheon and PPD businesses benefit from rising pharmaceutical outsourcing. As biopharma companies increasingly prefer to outsource manufacturing and trials rather than build internal capabilities, Thermo Fisher’s contract services revenue should grow faster than the company average.
4. China exposure — Asia-Pacific revenue is approximately 18% of total. China has been a headwind due to slower-than-expected post-COVID research investment recovery and government procurement preferences for domestic suppliers. How quickly China returns to normalised purchasing is a key near-term variable.
5. Next major acquisition — Thermo Fisher’s history shows a pattern of transformative acquisitions every 3–5 years (Life Technologies 2014, Patheon 2017, PPD 2021). The balance sheet supports another large deal. Potential targets in CRO services, genomics tools, or cell/gene therapy manufacturing have been widely speculated.

Thermo Fisher Scientific (TMO) Financial Summary

Thermo Fisher Scientific (TMO) is a life sciences company that generated $44.56B in total revenue in fiscal year 2025 (ended December 31, 2025), up 3.9% year-over-year. Laboratory Products & Biopharma Services was the largest segment at $23.98B (54% of revenue), followed by Life Sciences Solutions at $10.37B (23%), Analytical Instruments at $7.55B (17%), and Specialty Diagnostics at $4.68B (10%). The company earned $6.70B in net income at a 15.2% net margin and generated $6.29B in free cash flow. For a deeper look at Thermo Fisher’s revenue breakdown, business segments, and financial performance, review the detailed analysis above.